201 related articles for article (PubMed ID: 27912071)
1. Classical and alternative macrophages have impaired function during acute and chronic HIV-1 infection.
Galvão-Lima LJ; Espíndola MS; Soares LS; Zambuzi FA; Cacemiro M; Fontanari C; Bollela VR; Frantz FG
Braz J Infect Dis; 2017; 21(1):42-50. PubMed ID: 27912071
[TBL] [Abstract][Full Text] [Related]
2. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
[TBL] [Abstract][Full Text] [Related]
3. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
[TBL] [Abstract][Full Text] [Related]
4. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
[TBL] [Abstract][Full Text] [Related]
5. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
[TBL] [Abstract][Full Text] [Related]
6. HIV DNA and immune alteration during successful HAART.
Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
[TBL] [Abstract][Full Text] [Related]
7. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Patro SC; Azzoni L; Joseph J; Fair MG; Sierra-Madero JG; Rassool MS; Sanne I; Montaner LJ
J Leukoc Biol; 2016 Jul; 100(1):223-31. PubMed ID: 26609048
[TBL] [Abstract][Full Text] [Related]
9. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.
Clerici M; Seminari E; Maggiolo F; Pan A; Migliorino M; Trabattoni D; Castelli F; Suter F; Fusi ML; Minoli L; Carosi G; Maserati R;
AIDS; 2002 Sep; 16(13):1767-73. PubMed ID: 12218388
[TBL] [Abstract][Full Text] [Related]
10. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
11. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.
Walker-Sperling VE; Buckheit RW; Blankson JN
J Virol; 2014 Sep; 88(17):9789-98. PubMed ID: 24942573
[TBL] [Abstract][Full Text] [Related]
13. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
14. IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads.
Lozano JM; Kindelán JM; Cabello A; Gonzalez R; Solana R; Peña J
Int Immunopharmacol; 2006 Jun; 6(6):1034-8. PubMed ID: 16644491
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
16. [Innate immunity restoration in patients with HIV/AIDS infection associated with antiretroviral therapy].
Afani A; Jiusán L; Raby P; Sitia G; Puente J; Sepúlveda C; Miranda D; Cabrera R; Guidotti L; Lanza P
Rev Med Chil; 2006 Jun; 134(6):689-96. PubMed ID: 17130942
[TBL] [Abstract][Full Text] [Related]
17. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
18. Impact of ART on dynamics of growth factors and cytokines in primary HIV infection.
Bordoni V; Sacchi A; Casetti R; Cimini E; Tartaglia E; Pinnetti C; Mondi A; Gruber CEM; Antinori A; Agrati C
Cytokine; 2020 Jan; 125():154839. PubMed ID: 31542514
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
[TBL] [Abstract][Full Text] [Related]
20. T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
da Silva TP; Giacoia-Gripp CB; Schmaltz CA; Sant Anna FM; Rolla V; Morgado MG
PLoS One; 2013; 8(6):e66095. PubMed ID: 23840403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
